Quantcast

Latest Motavizumab Stories

2011-01-07 09:28:00

GAITHERSBURG, Md., Jan. 7, 2011 /PRNewswire/ -- MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases. Under the terms of the agreement, Amgen grants MedImmune rights to develop AMG...

2010-06-02 16:29:00

GAITHERSBURG, Md., June 2 /PRNewswire/ -- MedImmune today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants. The committee's recommendation will be considered by FDA reviewers in their evaluation of the Biologics License Application (BLA) for motavizumab. "We...

2010-05-03 11:05:00

GAITHERSBURG, Md., May 3 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, announced today that researchers will present results from five studies in the areas of respiratory syncytial virus (RSV) at the 2010 Pediatric Academic Societies (PAS) annual meeting taking place May 1-4, 2010 in Vancouver, BC, Canada. MedImmune abstracts to be presented at PAS regarding RSV include: Respiratory syncytial virus (RSV) Hospitalization in infants with Chronic Lung Disease (CLD):...

2010-01-29 13:00:00

GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of Pediatrics. Motavizumab is an investigational monoclonal antibody (MAb) being evaluated by the FDA for its potential to prevent serious disease caused by respiratory syncytial virus (RSV)...

2009-10-30 10:56:00

PHILADELPHIA, Oct. 30 /PRNewswire/ -- MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health. "MedImmune is dedicated to conducting ground-breaking research on the prevention of respiratory...

2009-10-16 13:18:00

WASHINGTON, Oct. 16 /PRNewswire/ -- MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2009 National Conference & Exhibition that add to the company's growing body of research on the burden of respiratory syncytial virus (RSV) on children, as well as pediatric infectious disease prevention. "With influenza and RSV becoming more widespread this time of year, it remains important to better understand the impact of infectious diseases on...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related